Jalota Deepika 4
4 · PMV Pharmaceuticals, Inc. · Filed Aug 18, 2021
Insider Transaction Report
Form 4
Jalota Deepika
Chief Development Officer
Transactions
- Exercise/Conversion
Stock option (right to buy)
2021-08-17−2,896→ 87,320 totalExercise: $3.53Exp: 2029-08-20→ Common Stock (2,896 underlying) - Exercise/Conversion
Common Stock
2021-08-17$3.53/sh+2,896$10,223→ 2,896 total - Sale
Common Stock
2021-08-17$33.78/sh−2,896$97,814→ 0 total
Footnotes (3)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $34.125, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F3]One-fourth of the shares subject to the option vested on June 10, 2020 and one forty-eighth of the shares subject to the option shall vest each month thereafter.